Advertisement
Advertisement
U.S. markets close in 4 hours 27 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Genfit SA (GNFTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
5.00000.0000 (0.00%)
As of 09:31AM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.0000
Open5.0000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range5.0000 - 5.0000
52 Week Range3.3700 - 6.6400
Volume325
Avg. Volume29
Market Cap248.633M
Beta (5Y Monthly)1.26
PE Ratio (TTM)N/A
EPS (TTM)-1.0750
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.92
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for GNFTF

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • GENFIT
    ENTA: Lowering target price to $65.00ENANTA PHARMACEUTICALS INC has an Investment Rating of BUY; a target price of $65.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    2 days agoArgus Research
View more
  • GlobeNewswire

    GENFIT: 2022 Financial Calendar

    Lille, France; Cambridge, MA; January 24, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced its provisional financial calendar for 2022. February 28, 2022: Publication of revenue and cash position at December 31, 2021 April 07, 2022: Publication of Full Year 2021 financial statements The 2020 Universal Registration Document and Annual Financial Report (included in the

  • GlobeNewswire

    GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

    Lille, France; Cambridge, MA; January 21, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial. Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the liquidity account as of December 31, 2021: 137,012 shares€512 873.86

  • Zacks

    Can GENFIT S.A. Unsponsored ADR (GNFT) Climb 79% to Reach the Level Wall Street Analysts Expect?

    The consensus price target hints at a 78.9% upside potential for GENFIT S.A. Unsponsored ADR (GNFT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Advertisement
Advertisement